Author: l.ferguson@neurotechusa.com

April 21, 2025

Neurotech Appoints Beth Marsh as Chief Commercial Officer

March 6, 2025

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Adults with Idiopathic Macular Telangiectasia Type 2 (MacTel)

Press Release – Neurotech receives approval for ENCELTO (revakinagene taroretcel-lwey)

February 4, 2025

Neurotech Announces Employee Recognition Program

January 1, 2025

Neurotech Executives Jim Mazzo, Chairman and Rich Small, Chief Executive Officer to Present at Annual J.P. Morgan Healthcare Conference

November 8, 2024

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

September 18, 2024

Neurotech’s Chief Executive Officer, Rich Small Presented a Company Update at the Ophthalmology Futures Retina Forum on September 18, 2024 in Barcelona, Spain

June 20, 2024

Chief Executive Officer, Rich Small Participates in the Panel Discussion ” Innovations and Applications in Genetic Engineering and Cell Transplantation” at Octane’s Ophthalmology Tech Forum in Newport Beach, California on June 20, 2024

June 20, 2024

Neurotech Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

May 9, 2024

Rich Small, Chief Executive Officer Joined the Panel Discussion, New Pathways in Retinal Diseases at the Retina World Congress on May 9, 2024 in Fort Lauderdale, Florida

May 4, 2024

Rich Small, Chief Executive Officer Provides a Company Update at the Retina Innovation Summit Showcase in Seattle, Washington on May 4, 2024